PROCEPT BioRobotics Corporation Common Stock
PRCTPROCEPT BioRobotics Corporation (PRCT) is a medical device company focused on developing innovative solutions for the treatment of benign prostatic hyperplasia (BPH). The company is known for its Water Vapor Therapy platform, which uses controlled water vapor to ablate excess prostate tissue, offering a minimally invasive option for patients. Founded to advance urological care, PROCEPT aims to improve patient outcomes with technology that simplifies BPH treatment procedures.
Company News
A securities fraud investigation into PROCEPT BioRobotics Corporation continues following the company's February 25, 2026 earnings report, which disclosed larger-than-expected adjusted EBITDA losses and cut full-year 2026 revenue guidance from $410-$430 million to $390-$410 million. The stock fell $4.21 per share (15.12%) to $23.63 on the news. T...
The Law Offices of Frank R. Cruz is investigating PROCEPT BioRobotics Corporation for possible federal securities law violations. On February 25, 2026, the company reported larger-than-expected adjusted EBITDA losses and cut its 2026 revenue guidance from $410-430 million to $390-410 million, citing reduced U.S. consumable revenue due to eliminat...
A securities fraud investigation has been launched into PROCEPT BioRobotics (NASDAQ: PRCT) following the company's February 25, 2026 earnings report, which disclosed larger-than-expected adjusted EBITDA losses and a significant downward revision of full-year 2026 revenue guidance from $410-$430 million to $390-$410 million. The announcement trigg...
The Law Offices of Frank R. Cruz announced an investigation into PROCEPT BioRobotics Corporation for possible violations of federal securities laws. The investigation follows the company's February 25, 2026 earnings report, which disclosed larger-than-expected adjusted EBITDA losses and a significant cut to full-year 2026 revenue guidance from $4...
The Schall Law Firm is investigating PROCEPT BioRobotics Corporation for potential securities law violations. The company reported Q4 2025 results on February 25, 2026, with quarterly revenue significantly below analyst expectations and substantially reduced full-year guidance. The company attributed underperformance to realignment disruptions an...
